Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models

Executive Summary

In unveiling the agency’s Biosimilar Action Plan, FDA's Gottlieb continued his pattern of provocative remarks by criticizing brand company practices and payment models that impede biosimilar competition and could ultimately undermine innovation. He also called for more action by the Federal Trade Commission and downplayed the impact interchangeability could have on biosimilar uptake. 


Advertisement

Related Content

Trade Pact War: Generic Stakeholders Push For Changes To US-Mexico-Canada Deal, Seek FDA Intervention
Trade Pact War: Generic Stakeholders Push For Changes To US-Mexico-Canada Deal, Seek FDA Intervention
Fix Antibiotic Payment Models To Spur R&D Investment, US FDA’s Gottlieb Says
Mehta Analysis: From Generics To Biosimilars – When Will History Hurry Up And Repeat Itself?
Mehta Analysis: From Generics To Biosimilars – When Will History Hurry Up And Repeat Itself?
From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive
Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown
Part B Drug Competitive Bidding Program Revival: Vendor Request Coming Soon
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123447

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel